The global research antibodies market size is worth USD 11.6 Billion in 2024 and is anticipated to reach USD 17.8 Billion by 2029 with a CAGR of 6.8% in the forecast period.
The bio-scientists use research antibodies as the fundamental detection tools. An antibody is a protective protein that is produced by the immune system in response to the presence of antigens. It plays a crucial role in conducting genomics and proteomic analysis. B cells produce antibodies, which are crucial for the human immunity system. The research antibodies are helpful in the detection, measurement, and purification of proteins or biomolecules in various applications. Antibodies have various research applications, such as diagnostic tests and therapeutics. Only some of the primary antibodies are suitable for all applications.
The increasing investments in medical and research activities in the world healthcare system drive the growth of the research antibodies market. Increasing government initiatives in various developed countries Various regional governments are considering R&D as the prominent aspect of the nation; international competitiveness and public benefit fuel the market expansion. These factors were significant reasons for the increased expenditure and funding for research activities, which is expected to witness steady market growth in the forecast period. According to CBRE Research, the R&D expenditures by US Life sciences companies have shown nearly 40% growth over the last five years. The demand for antibodies is enormous in the pharmaceutical industry, where antibodies have marked pharmaceutical companies' landscape, and in the present situation, antibodies are one of the fastest-growing therapeutics. According to various articles, half of the drugs introduced to the market in 2022 are antibody-based drugs. All these factors are expected to witness lucrative growth in the research antibodies market during the forecast period.
The research antibodies market is expanding its revenue due to increasing research institutions, industry collaborations, and rising investments in proteomics research, where research antibodies play an essential role in pharmaceutical and biotechnology companies. This factor is estimated to witness lucrative growth opportunities for market expansion. Another factor augmenting the market growth is the growing prevalence of neurodegenerative diseases and cancer. The growing cases of diseases like multiple sclerosis, Parkinson's, and Huntington's are creating market-growing possibilities for research antibodies.
The increasing demand for protein therapies and personalized medicine is creating growth opportunities in the market. The rising technological advancements in the purification of antibodies are estimated to add fuel to the market growth. The rising government support for research in developing novel vaccines and therapeutic techniques for treating diseases is projected to have market growth opportunities over the forecast period. Governments worldwide are increasingly focused on researching and developing new drugs and therapies for preventing diseases. For these reasons, they provide funding and support to research activities to develop new vaccines, drugs, and therapies.
The major restraining factor for the research antibodies is the high production cost. The high costs of research antibodies limit market expansion as they are difficult to afford for smaller research institutions and individual researchers, hampering market growth. Another factor hindering the market growth is time consumption. The antibody development requires more time for manufacturing, and the final product should pass the quality control and regulatory bodies' approval, where all these processes take time and are complex. Developing research antibodies requires significant investment, and quality checks and regulatory compliance are expected to increase production costs.
The need for more skilled professionals, which results in the product's lack of quality and effectiveness, is challenging for market growth. As the research involves success and failure in the results, the lack of reproducible results and quality concerns are sometimes challenging for market expansion.
The Pandemic was impacted by a significant rise in research activities to develop diagnostic and therapeutic methods for COVID-19. This increased the funds developed by public and private entities for research activities. For Instance, In April 2020, Emergent BioSolutions, a biopharmaceutical company, received USD 14.5 Million from the federal government to work on the antibody therapy study for COVID-19. The prominent development of vaccines and medicines based on research antibodies during the Pandemic leads to global market growth opportunities in the forecast period.
REPORT METRIC |
DETAILS |
Market Size Available |
2023 to 2029 |
Base Year |
2023 |
Forecast Period |
2024 to 2029 |
Segments Covered |
By Product, Type, Technology, Source, Application, End-Use, and region. |
Various Analyses Covered |
Global, Regional & Country Level Analysis, Segment-Level Analysis, Drivers, Restraints, Opportunities, Challenges; PESTLE Analysis; Porter's Five Forces Analysis; Competitive Landscape; Analyst Overview of Investment Opportunities |
Regions Covered |
North America, Europe, Asia Pacific, Latin America, Middle East & Africa |
Market Leaders Profiled |
Abcam Plc., Merck KGaA, Thermo Fischer Scientific, Inc., Cell Signalling Technology, Inc., Santa Cruz Biotechnology Inc., Bio-Techne Corporation, PerkinElmer, Inc., Jackson ImmunoResearch Inc., Proteintech Group, Inc., Becton, Dickinson, and Company |
The primary antibodies segment dominated the global research antibodies market in 2024 with the largest revenue share of 73.56%. The growing availability of primary antibodies using rabbit, mouse, goat, and other species and the wide range of applicability in R&D are driving the market growth in this segment.
The secondary antibodies segment is expected to have significant growth with prominent CAGR during the forecast period as these are cost-effective and convenient to develop. As these are available in ready-to-use conjugated antibodies, the demand for secondary antibodies, which are expected to improve product development activities, is rising.
Monoclonal antibodies will dominate the global market revenue in 2023 due to increasing cancer research, which demands specific antibodies. The monoclonal antibodies are efficient in blocking the antigens on cancer cells, which is beneficial in identifying and developing cancer medicines. The cancer study is the primary factor boosting this segment's market value growth.
The Polyclonal antibodies segment is projected to grow with a significant CAGR over the forecast period. The secondary antibodies are required to focus on the purification of antigens and examination. Polyclonal antibodies are beneficial in providing stability, storage methods, affinity, and compatibility in techniques like ELISA and western blotting.
The western blotting segment witnessed the most significant market share in 2024 due to its wide availability and adoption of the technique. The increasing demand for the technique is due to its accuracy and is typically adopted over alternative techniques for detecting prominent protein entities. All these factors influence the segment, which is increasing the market revenue.
The Immunohistochemistry segment will increase with a significant CAGR in the forecast period. The various applications of the technique in the detection of enzymes, antigens, and others influence the segment to have steady growth during the forecast period. The growing technological advancements in the techniques are increasing R&D spending, and growing prospects of the technique are driving market share growth in the forecast period.
The rabbit source segment dominated the global market in 2023 as rabbits are widely used for antibody production with several advantages. The rabbit antibodies have a high affinity compared to other animal hosts. The rabbit antibantibodies' specificity allows them to detect small molecules, hormones, toxins, and other substances.
The mouse source segment is expected to grow fastest during the forecast period. Mice are widely used for antibody production due to their smaller size and high reproduction rate. The structural similarity of human and mouse antibodies is significantly propelling the growth of the R&D market.
The oncology segment held the largest share in the research antibodies market in 2024 due to the rising prevalence of cancer in various regions. According to the American Cancer Society, in 2021, over 1.9 cancer cases were reported in the US, and nearly 608,536 cancer deaths were recorded in the US. These influence the development of research antibodies used for designing and evaluating new diagnostic and therapeutic approaches.
The stem cells segment is projected to proliferate over the forecast period due to increasing research worldwide. Stem cells are expected to treat chronic diseases such as cancer, diabetes, Alzheimer's, and others. Antibodies are used in stem cells for disease modeling, drug screening, development, and cell therapy, positively impacting growth.
The academic and research institutes held the largest market share in 2024 and are estimated to dominated during the forecast period. The increasing scientific initiatives for developing novel therapies and tests for chronic diseases are driving the market expansion in this segment.
The Pharmaceutical and biotechnology companies are projected to show lucrative growth during the forecast period. Rising technological advancements in the research for developing antibodies to fight against chronic diseases and government support in developing pharmaceutical and biotechnology companies worldwide.
The North American region dominated the global market with the most significant share of 41.5% in 2023. North America ranks at the top with advanced research institutes and pharmaceutical companies, which is driving the research antibodies market in the region. The presence of market key players is adding fuel to the market expansion. The growing government concerns and funding for research and development activities to bring the best output to the public is boosting the market revenue in the region.
The Asia Pacific region is projected to be the fastest-growing research antibodies market in the forecast period. The increasing collaborative activities among the academic institutions in the region are propelling market growth.
Abcam Plc., Merck KGaA, Thermo Fischer Scientific, Inc., Cell Signalling Technology, Inc., Santa Cruz Biotechnology Inc., Bio-Techne Corporation, PerkinElmer, Inc., Jackson ImmunoResearch Inc., Proteintech Group, Inc., Becton, Dickinson, and Company
Primary Antibodies
Frequently Asked Questions
The growth of the Research Antibodies Market is influenced by factors such as increasing investment in life science research, a rise in the prevalence of infectious diseases, and advancements in antibody technologies.
Challenges include issues related to antibody specificity and reproducibility. The industry is addressing these challenges through rigorous validation processes, improved antibody engineering, and collaborations between researchers and manufacturers.
Trends include a growing focus on single-cell analysis, the rise of therapeutic antibodies, increased collaboration between academia and industry, and the integration of artificial intelligence in antibody development processes for improved efficiency.
Related Reports
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2500
Didn’t find what you’re looking for?
TALK TO OUR ANALYST TEAM
Need something within your budget?
NO WORRIES! WE GOT YOU COVERED!
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: [email protected]
Reports By Region